Whereas SGLT-2 inhibitors have clearly shown benefits in HF hospitalizations in patients with (20–24) and without T2D (25, 26), GLP-1 receptor agonists have not been demonstrated to lead to significant reductions in HF hospitalizations (9–16). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.